SEC Form 4 · accession 0001225208-18-000493
BOSTON SCIENTIFIC CORP · BSX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael P. Phalen
Officer — EVP & President, MedSurg
Period of report
Dec 29, 2017
Accepted (ET)
Jan 3, 2018 · 7:53 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000885725
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Dec 29, 2017 | M | 15,835 | $7.16 | A | 113,745 | D | |
| Common StockF3,F2 | Dec 29, 2017 | S | 15,835 | $25.252 | D | 97,910 | D | |
| Common StockF4,F2 | Jan 1, 2018 | M | 13,341 | $0.00 | A | 111,251 | D | |
| Common StockF2 | Jan 1, 2018 | F | 4,578 | $24.79 | D | 106,673 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F5 | $7.16 | Dec 29, 2017 | M | 15,835 | D | — | Feb 28, 2021 | Common Stock | 15,835 | 0 | D |
| Performance Share UnitsF4,F6 | — | Jan 1, 2018 | M | 13,341 | D | Dec 31, 2017 | Dec 31, 2017 | Common Stock | 13,341 | 0 | D |
Explanation of responses
- F1This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.
- F2Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.
- F3Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.24 to $25.26, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F4On February 23, 2015, the reporting person was awarded a target number of performance share units under the Company's 2015 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2015 adjusted free cash flow measured against its 2015 financial plan over the one-year performance period ending December 31, 2015 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2016, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2017.
- F5Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2012, the first anniversary of the date of grant.
- F6Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock.
Remarks
phalenpoa.txt